Viatris (VTRS) Non-Current Assets (2019 - 2026)
Viatris (VTRS) posted Non-Current Assets of $25.0 billion for Q2 2026, down 3.58% on a QoQ basis from $25.9 billion in Q1 2026, and down 12.74% year-over-year from $28.6 billion in Q2 2025.
Analysis
Viatris (VTRS) Non-Current Assets (2019 - 2026) Analysis & Trends
Viatris has reported Non-Current Assets for 8 years, with the latest figure at $25.0 billion in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 12.74% year-over-year to $25.0 billion in Q2 2026; TTM through Jun 2026 was $106.3 billion, a 13.53% decrease from a year earlier, with the FY2025 full-year figure at $27.4 billion, down 14.31% from the prior year.
- Non-Current Assets was $25.0 billion for Q2 2026 at Viatris, down from $25.9 billion in the prior quarter.
- The five-year high for Non-Current Assets was $41.7 billion in Q1 2022, with the low at $25.0 billion in Q2 2026.
- Average Non-Current Assets over 5 years is $33.7 billion, with a median of $34.0 billion recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 7877260.0% in 2022, then fell 16.38% in 2025.
- Over 5 years, Non-Current Assets stood at $39.4 billion in 2022, then slipped by 11.88% to $34.7 billion in 2023, then fell by 7.86% to $32.0 billion in 2024, then declined by 14.31% to $27.4 billion in 2025, then fell by 8.81% to $25.0 billion in 2026.
- The last three Non-Current Assets figures came in at $25.0 billion (Q2 2026), $25.9 billion (Q1 2026), and $27.4 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | 26.10 Bn |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn | 24.99 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 2.92 Bn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn | 1.83 Bn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 18.27 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | 1.04 Bn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 668.68 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 1.11 Bn |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn | 3.25 Mn |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - | 18.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.99 Bn |
| Mar 31, 2026 | 25.92 Bn |
| Dec 31, 2025 | 27.40 Bn |
| Sep 30, 2025 | 27.97 Bn |
| Jun 30, 2025 | 28.64 Bn |
| Mar 31, 2025 | 28.85 Bn |
| Dec 31, 2024 | 31.98 Bn |
| Sep 30, 2024 | 33.45 Bn |
| Jun 30, 2024 | 33.54 Bn |
| Mar 31, 2024 | 34.42 Bn |
| Dec 31, 2023 | 34.71 Bn |
| Sep 30, 2023 | 37.81 Bn |
| Jun 30, 2023 | 38.92 Bn |
| Mar 31, 2023 | 39.66 Bn |
| Dec 31, 2022 | 39.39 Bn |
| Sep 30, 2022 | 38.17 Bn |
| Jun 30, 2022 | 39.95 Bn |
| Mar 31, 2022 | 41.72 Bn |
| Dec 31, 2021 | 500,000.00 |
| Sep 30, 2021 | 44.76 Bn |